Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration

International Journal of Antimicrobial Agents

Volumn 48, Issue 3, 2016, Pages 337-341

  Karaiskos, Ilias ^a   Friberg, Lena E ^b   Galani, Lambrini ^a   Ioannidis, Konstantinos ^a   Katsouda, Emmanouela ^a   Athanassa, Zoe ^a   Paskalis, Harris ^a   Giamarellou, Helen ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

CMS; Colistin; CVHHDF; Loading dose; Pharmacokinetics

Indexed keywords

COLISTIMETHATE; ANTIINFECTIVE AGENT; COLISTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DETERMINATION; FEMALE; HUMAN; INFECTION; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; CHEMISTRY; CRITICAL ILLNESS; HEMODIAFILTRATION; MIDDLE AGED; PLASMA; STATISTICAL MODEL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; COLISTIN; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA; TANDEM MASS SPECTROMETRY;

EID: 84984844827     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.06.008     Document Type: Article

References (22)

1. [1] Karaiskos, I., Giamarellou, H., Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15 (2014), 1351–1370.
2. [2] Udy, A.A., Roberts, J.A., Lipman, J., Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39 (2013), 2070–2082.
3. [3] Li, J., Rayner, C.R., Nation, R.L., Deans, R., Boots, R., Widdecombe, N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49 (2005), 4814–4815.
4. [4] Markou, N., Fousteri, M., Markantonis, S.L., Zidianakis, B., Hroni, D., Boutzouka, E., et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 67 (2012), 2459–2462.
5. [5] Karvanen, M., Plachouras, D., Friberg, L.E., Paramythiotou, E., Papadomichelakis, E., Karaiskos, I., et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57 (2013), 668–671.
6. [6] Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53 (2009), 3430–3436.
7. [7] Mohamed, A.F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56 (2012), 4241–4249.
8. [8] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
9. [9] Karaiskos, I., Friberg, L.E., Pontikis, K., Ioannidis, K., Tsagkari, V., Galani, L., et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate (CMS) in critically ill patients. Antimicrob Agents Chemother 59 (2015), 7240–7248.
10. [10] Pickering, J.W., Frampton, C.M., Walker, R.J., Shaw, G.M., Endre, Z.H., Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care, 16, 2012, R107.
11. [11] Jansson, B., Karvanen, M., Cars, O., Plachouras, D., Friberg, L.E., Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 49 (2009), 760–767.
12. [12] Li, J., Milne, R.W., Nation, R.L., Turnidge, J.D., Coulthard, K., Valentine, J., Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46 (2002), 3304–3307.
13. [13] Kumar, A., Roberts, D., Wood, K.E., Light, B., Parrillo, J.E., Sharma, S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006), 1589–1596.
14. [14] Liang, S.Y., Kumar, A., Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. Curr Infect Dis Rep, 17, 2015, 493.
15. [15] European Committee on Antimicrobial Susceptibility Testing, EUCAST. Clinical breakpoints. http://www.eucast.org/clinical_breakpoints/, 2016 [accessed 01.01.16].
16. [16] Honoré, P.M., Jacobs, R., Joannes-Boyau, O., Lochy, S., Boer, W., De Waele, E., et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 37 (2014), 291–295.
17. [17] Dalfino, L., Puntillo, F., Ondok, M.J., Mosca, A., Monno, R., Coppolecchia, S., et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61 (2015), 1771–1777.
18. [18] Nation, R.L., Garonzik, S.M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E.J., Paterson, D.L., et al. Updated US and European dose recommendations for intravenous colistin: how do they perform?. Clin Infect Dis 62 (2016), 552–558.
19. [19] Landersdorfer, C.B., Nation, R.L., Colistin: how should it be dosed for the critically ill?. Semin Respir Crit Care Med 36 (2015), 126–135.
20. [20] Jamal, J.A., Mueller, B.A., Choi, G.Y., Lipman, J., Roberts, J.A., How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. Diagn Microbiol Infect Dis 82 (2015), 92–103.
21. [21] Li, J., Milne, R.W., Nation, R.L., Turnidge, J.D., Coulthard, K., Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 47 (2003), 1364–1370.
22. [22] Bouchene, S., Friberg, L.E., Comparison of the rate and extent of in vitro formation of colistin for different brands of colistimethate sodium (CMS). In: 2nd International conference on polymyxins; San Diego, CA [abstract P-2]; 22–24 September, 2015.